4th Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$260,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Biosimilar Naming, Issues related to implementation of the Generic Drug User Fee Agreement, generic drug pricing Medicaid Generic Drug Rebate, Bipartisan Budget Act of 2015, H.R. 1314

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; Health & Human Services, Dept of (HHS); White House Office; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC)

Bills named: H.R. 1314 (114th)

Trade (domestic/foreign) TRD

Issues related to Trans Pacific Partnership(TPP), General trade issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); U.S. Trade Representative (USTR); SENATE

Copyright/Patent/Trademark CPT

Patent Reform, H.R. 9 Innovation Act, S. 632 STRONG Patents Act, S. 1137, the Patent Act, S. 2019 Preserve Access to Affordable Generics Act

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Federal Trade Commission (FTC); SENATE; Health & Human Services, Dept of (HHS); White House Office

Bills named: H.R. 9 (114th), S. 1137 (114th), S. 2019 (114th), S. 632 (114th)

Health Issues HCR

Biosimilar Naming, Issues related to implementation of the Generic Drug User Fee Agreement, generic drug pricing Issues related to Senate HELP Innovation Initiative Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, H.R. 2841 FAST generics Act S. 1972 Airline Access to Emergency Epinephrine Act of 2015, Anaphylaxis awareness, access to epinephrine auto injector

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office

Bills named: S. 1972 (114th), H.R. 2841 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.